Principal Healthcare Innovators Index ETF BTEC 深 沪
已收盘 07-31 16:00:00 美东时间
39.49
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 39.49
- 总市值 4738.80万
- 52周最高 41.10
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 25.66
- 委 比 0.00%
- 总股本 120.00万
- 历史最高 72.9268
- 量 比 0
- 振 幅 0.00%
- 历史最低 21.62
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Abivax raises $920M as underwriters fully exercise overallotment option
Abivax (ABVX) said the underwriters of its U.S. public offering have fully exercised their option to purchase an additional 960K American Depositary Shares (ADSs). With the overallotment option fully ...
07-02 19:06
Abivax SA prices upsized $800M ADS offering
Abivax SA (ABVX) priced an upsized public offering of 6.4M ADSs at $125/ADS, raising ~$800M in gross proceeds. The offering size was increased from the previously announced $600M. The company granted ...
07-01 20:56
Abivax launches $600M underwritten public offering
Abivax SA (ABVX) on Tuesday announced the launch of an underwritten public offering of ~$600M of its American Depositary Shares, each representing one ordinary share of Abivax, nominal value €0.01 per...
07-01 05:02
Abivax stock jumps on positive Phase 3 ulcerative colitis data
Abivax SA (ABVX) shares surged Tuesday premarket after the biotech reported positive topline supplemental data from its Phase 3 ulcerative colitis maintenance program, delivering strong efficacy while...
06-30 15:49
What's Going On With Abivax Stock On Thursday?
Abivax's Phase 3 ulcerative colitis data met remission goals, but cancer cases in the study raised safety questions and analyst caution.
06-04 22:35
Why Is Abivax Stock Sinking Tuesday?
Abivax shares plunge more than 35% as cancer cases reported in a Phase 3 trial overshadow strong efficacy results for ulcerative colitis drug.
06-02 20:49
Market-Moving News for June 2nd
HPE: 30% | Hewlett Packard Enterprise shares are trading higher after the company reported better-than-expected Q2 financial results BJDX: 200% | Bluejay Diagnostics Announces Strategic Partnership With
06-02 19:24
Abivax's Phase 3 ABTECT Maintenance Trial Of Obefazimod Met Primary Endpoint Of Clinical Remission And All Key Secondary Endpoints At Week 44 In Ulcerative Colitis
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative ColitisAt Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary
06-02 04:08
Abivax Reports Long-Term Study 108 Data Showing Obefazimod Maintains Durable Clinical Remission In Ulcerative Colitis For Up To Seven Years With No New Safety Signals
Interim intent to treat ("ITT") analysis from Study 108 supports strong durable clinical remission in moderately to severely active ulcerative colitis ("UC") patients treated with obefazimod Following two to four
05-23 04:07
BRIEF-Wabtec Announces First Quarter 2026 Earnings Release Date
BRIEF-Wabtec Announces First Quarter 2026 Earnings Release Date March 30 (Reuters) - Westinghouse Air Brake Technologies Corp WAB.N : WABTEC ANNOUNCES FIRST QUARTER 2026 EARNINGS RELEASE DATE Source text: ID:nBw1c4qBMa Further company coverage: WAB.N (( Reuters.Briefs@thomsonreuters.com ;))
03-30 22:09
